Telix Welcomes Anne Whitaker to Board, Strengthening U.S. Ties

Telix Pharmaceuticals has announced the appointment of Anne Whitaker as a U.S.-based Non-Executive Director, effective April 7, 2025. With over three decades of experience across the pharmaceutical, biotech, and specialty drug sectors, Ms. Whitaker brings a powerful blend of clinical, commercial, and governance expertise. Her previous leadership roles at industry giants like GlaxoSmithKline, Sanofi, and Bausch Health—along with her most recent position as Chair and CEO of Aerami Therapeutics—make her a valuable asset to Telix’s strategic global expansion.

Currently serving as Chair of QurAlis Corporation and a Non-Executive Director at ICON plc (NASDAQ: ICLR), Ms. Whitaker has deep experience navigating the complexities of Nasdaq-listed organizations. Telix Chairman H Kevin McCann AO expressed his confidence in her addition to the board, noting her “industry-relevant expertise across commercial risk management, M&A, and governance.” As Telix continues to grow its global footprint, Anne Whitaker’s appointment signals a bold step forward in strengthening the company’s international leadership and strategic outlook.